Key result
ICD or CRT monotherapy was associated with a higher risk of all-cause death compared with CRT-ICD combined therapy in patients with heart failure (OR 1.348, P<0.001).
Why the study?
Does CRT-ICD combined therapy reduce death or hospitalization compared to ICD or CRT monotherapy in patients with heart failure?
Meta-Analysis (n=7,679)
Does CRT-ICD combined therapy reduce death or hospitalization compared to ICD or CRT monotherapy in patients with heart failure?
CRT-ICD combined therapy is associated with lower all-cause mortality and reduced risk of death or heart failure hospitalization compared to ICD or CRT monotherapy in patients with heart failure.
CRT-ICD combination improves survival versus monotherapies in heart failure; extends evidence by pooling nine comparative studies.
The aim of this meta-analysis was to compare the efficacy of implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy (CRT) monotherapies with CRT-ICD combined therapy. Databases were searched to identify studies that compared CRT or ICD alone with CRT-ICD combined therapy in patients with heart failure. The primary outcome was rate of death for any cause, and secondary outcomes included rate of death or hospitalization due to heart failure or any cause. Nine studies with 7679 patients were included. Combined data of ICD and CRT monotherapies found that there was a higher risk of all-cause death (odds ratio [OR] 1.348, P < 0.001) and death or hospitalization from heart failure (OR 1.368, P < 0.001) with monotherapy compared with CRT-ICD combined therapy. No significant difference was observed between mono and combined therapy groups for risk of death or hospitalization from any cause (OR 1.292, P = 0.083). Compared with ICD or CRT monotherapy, CRT-ICD therapy had favorable outcomes regarding all-cause death and the risk of hospitalization or death due to heart failure.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2015) conducted a meta-analysis in Heart failure (n=7,679). ICD or CRT monotherapy vs. CRT-ICD combined therapy was evaluated on Rate of death for any cause (OR 1.348, p=<0.001). ICD or CRT monotherapy was associated with a higher risk of all-cause death compared with CRT-ICD combined therapy in patients with heart failure (OR 1.348, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: